Compare iShares 0 3 Month Treasury Bond ETF (SGOV) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 0 3 Month Treasury Bond ETF vs Zoetis Inc — how do they compare? iShares 0 3 Month Treasury Bond ETF trades at $100.52 (market cap $114.40B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: iShares 0 3 Month Treasury Bond ETF is far larger — about 3.8× Zoetis Inc's market cap, and Zoetis Inc pays a 2.9% dividend while iShares 0 3 Month Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares 0 3 Month Treasury Bond ETF for 50 Days and Zoetis Inc for 70 Days on average.
| SGOV | ZTS | |
|---|---|---|
Market Cap | $114.40B | $30.20B |
Volume | 18,879,081 | 6,175,327 |
Sector | Fixed Income | Health |
52-Week High | $100.72 | $147.53 |
52-Week Low | $100.28 | $69.09 |
Typical Hold Time | 50 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SGOV (iShares 0-3 Month Treasury Bond ETF) trades at $100.47 with minimal daily price movement, reflecting its ultra-short-term Treasury bond focus. The technical picture shows bearish momentum with moving averages signaling caution, while oscillators remain neutral. Recent corporate actions include consistent dividend distributions around $0.30-0.31 per share through mid-2026.
As a Treasury bond ETF, SGOV offers low volatility and regular income but faces headwinds from rising interest rates. The fund provides exposure to short-term government debt with minimal credit risk, though higher yields elsewhere may pressure returns. Current bond market volatility creates both challenges and opportunities for short-term fixed income investors.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
